Universal Technical Institute (UTI) is a Great Momentum Stock: Should You Buy?

Universal Technical Institute (UTI) is highlighted as a strong momentum stock, currently holding a Zacks Rank #2 (Buy) and a Momentum Style Score of B. UTI's stock has significantly outperformed both its industry and the S&P 500, with a 32.1% increase over the past quarter and a 118.72% increase over the past year, coupled with a 20-day average trading volume of 1,092,414 shares. Positive earnings estimate revisions have also contributed to UTI's favorable outlook, with the full-year consensus estimate rising from $1.01 to $1.06 in the past 60 days.

Analysis

Universal Technical Institute (UTI) is exhibiting strong momentum characteristics, underpinned by a Zacks Rank #2 (Buy) and a Momentum Style Score of B. The company's stock has demonstrated significant outperformance relative to both its industry and the broader market. Specifically, UTI shares have appreciated 1.07% over the past week, contrasting with a 1.34% decline in the Zacks Schools industry. Over a longer horizon, the stock's monthly price change of 26.72% far outpaces the industry's 2.02% gain. Furthermore, UTI's shares have risen 32.1% in the past quarter and an impressive 118.72% in the last year, compared to S&P 500 movements of 1.35% and 13.07% respectively. This price performance is supported by a healthy average 20-day trading volume of 1,092,414 shares. Crucially, the positive momentum is also reflected in its earnings outlook; over the past two months, four analysts have revised full-year earnings estimates upwards, with none revising lower, leading to a consensus estimate increase from $1.01 to $1.06 per share. For the next fiscal year, three estimates have moved higher against one downward revision. This combination of strong price action and positive earnings estimate revisions suggests a robust underlying trend for UTI.

Key Decisions for Investors

• Given UTI's Zacks Rank #2 (Buy), Momentum Style Score of B, and strong outperformance, investors might consider UTI for portfolios seeking exposure to momentum-driven growth, particularly over a one-month horizon as suggested by Zacks' research.
• Investors should monitor UTI's earnings estimate revisions and trading volume closely, as continued positive trends in these areas would further support the bullish momentum thesis.
• While UTI shows strong momentum, investors should be mindful of the inherent strategy of 'buying high, hoping to sell even higher' and manage risk accordingly, particularly by watching for any signs of trend reversal or weakening relative strength.